CAAP Company: Conavi Medical, China Grand Pharmaceutical & Healthcare Enter Distribution Agreement for Minimally Invasive Imaging Technologies in China

2015 CAAP Company Conavi Medical Inc., a privately-held company developing image guidance technologies for minimally invasive procedures announced that it has entered into an agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Limited (CG Healthcare) to serve as the exclusive distributor of its ForesightTM Intracardiac Echocardiography (ICE) and NovasightTM Hybrid Intravascular Imaging systems in China, Hong Kong, Taiwan and Macau.

This agreement represents an important commercial milestone for Conavi. China has the second largest volume of cardiovascular interventional procedures in the world and is growing quickly as a result of extensive investments in healthcare infrastructure. We are delighted to have found a partner that shares our vision of bringing the potential benefits of advanced image guidance to a broad range of existing and emerging minimally invasive cardiovascular procedures to patients in China.
— Dr. Brian Courtney, President and CEO, Conavi

For the full press release click here

Previous
Previous

CCAB Welcomes Mr. Robert Verhagen as New CEO

Next
Next

Canadian Technology Accelerator (CTA) Initiative Accepting Applications - Spring 2018 Cohorts (February–June 2018)